Skip to main content
. 2023 Feb 2;13:1130852. doi: 10.3389/fonc.2023.1130852

Figure 4.

Figure 4

In vivo efficacy of pevonedistat and bortezomib. (A) In vivo growth of three PDX cohorts (n=5), treated for four weeks respectively with vehicle, bortezomib (0.5mg/kg) and pevonedistat (90mg/kg). (B) T-test p-values comparing tumor size in the vehicle cohort vs. the bortezomib or pevonedistat cohort, at different treatment times. (C, D) Kaplan-Meier survival plots comparing the vehicle cohort vs the bortezomib (C) or pevonedistat (D) cohorts. P-values are from Longrank test analysis. (E) Representative pictures of IHC staining for Ki67 after PDX treatment with vehicle, bortezomib and pevonedistat, at the end of the experiment.